Literature DB >> 11328209

Osteoporosis prevention in myasthenia gravis: a reminder.

S J Lewis1, P E Smith.   

Abstract

OBJECTIVES: Consensus guidelines for bone management of patients taking corticosteroids suggest two main interventions: Dual energy X-ray absorptiometry (DEXA) scanning in those taking prednisolone > or =7.5 mg daily for > or =6 months (repeated every 1-3 years as indicated). Bisphosphonate therapy for those taking prednisolone > or =15 mg daily for > or =6 months regardless of DEXA result, and also for patients with known or high risk of developing osteoporosis (including those aged >65 years).
MATERIAL AND METHODS: We audited adherence to these guidelines in all adults with myasthenia gravis (MG) attending our neurology service.
RESULTS: Of 80 patients with MG (47 male, mean age 63.3 years), 34 (43%) had received corticosteroids for > or =6 months. Eighteen were taking prednisolone > or =7.5 mg daily (mean dose 16.6 mg) yet only 4 of these (22%) had undergone DEXA scanning. Of the 13 patients meeting the guideline criteria to receive bisphosphonate therapy, this was prescribed to only 7 (54%). Two others were prescribed vitamin D, 2 a calcium supplement and 2 were receiving no prophylaxis.
CONCLUSION: In these MG patients the guidelines were followed in only a minority. Neurologists need greater awareness of the bone health consequences of prescribing long-term corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328209     DOI: 10.1034/j.1600-0404.2001.103005320.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Transient muscle paralysis degrades bone via rapid osteoclastogenesis.

Authors:  Antonios O Aliprantis; Marina Stolina; Paul J Kostenuik; Sandra L Poliachik; Sarah E Warner; Steven D Bain; Ted S Gross
Journal:  FASEB J       Date:  2011-11-28       Impact factor: 5.191

2.  Exacerbation of myasthenia gravis by alendronate.

Authors:  S Kesikburun; U Güzelküçük; S Alay; F Yavuz; A K Tan
Journal:  Osteoporos Int       Date:  2014-06-17       Impact factor: 4.507

Review 3.  Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines.

Authors:  M Duyvendak; M Naunton; E N van Roon; G A W Bruyn; J R B J Brouwers
Journal:  Osteoporos Int       Date:  2008-07-16       Impact factor: 4.507

Review 4.  Bone and skeletal muscle: neighbors with close ties.

Authors:  Douglas J DiGirolamo; Douglas P Kiel; Karyn A Esser
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

5.  Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study.

Authors:  Seung Woo Kim; Eun Hwa Kim; Jinae Lee; Young-Chul Choi; Seung Min Kim; Ha Young Shin
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.